CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
4.040
+0.120 (3.06%)
Mar 25, 2026, 4:00 PM EDT - Market closed
CervoMed Revenue
In the year 2025, CervoMed had annual revenue of $4.01M, down -58.86%. CervoMed had revenue of $8.73K in the quarter ending December 31, 2025, a decrease of -99.60%.
Revenue (ttm)
$4.01M
Revenue Growth
-58.86%
P/S Ratio
9.34
Revenue / Employee
$267,101
Employees
15
Market Cap
37.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.01M | -5.73M | -58.86% |
| Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
| Dec 31, 2023 | 7.14M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 71.67K | -302.88K | -80.87% |
| Dec 31, 2012 | 374.54K | -195.93K | -34.35% |
| Dec 31, 2011 | 570.48K | 530.29K | 1,319.48% |
| Dec 31, 2010 | 40.19K | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 40.19K | -268.57K | -86.98% |
| Dec 31, 2007 | 308.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Atara Biotherapeutics | 120.77M |
| Celularity | 40.58M |
| Veru Inc. | 16.89M |
| NovaBay Pharmaceuticals | 10.30M |
| Palatin Technologies | 8.96M |
| Apollomics | 6.93M |
| Werewolf Therapeutics | 1.14M |
| Actinium Pharmaceuticals | 90.00K |
CRVO News
- 7 days ago - CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology - GlobeNewsWire
- 9 days ago - CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 22 days ago - CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies - GlobeNewsWire
- 5 weeks ago - CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - GlobeNewsWire
- 3 months ago - CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - GlobeNewsWire
- 4 months ago - CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) - GlobeNewsWire
- 4 months ago - CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 5 months ago - CervoMed to Present at the Emerging Growth Conference - GlobeNewsWire